Jie Chen

US Patent:

6737431, May 18, 2004

Filed:

Mar 6, 2003

Appl. No.:

10/383131

Inventors:

Katherine S. Takaki - Middletown CT
Li-Qiang Sun - Glastonbury CT
Graham Johnson - Madison CT
Stephen R. Bertenshaw - Cheshire CT
Derek Denhart - Durham CT
Jie Chen - Madison CT

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31423

US Classification:

514375, 548217, 548224

Abstract:

Novel benzoxazole derivatives which have a binding affinity for the human melatonin receptor and, therefore, are useful as melatonergic agents.

US Patent:

6831080, Dec 14, 2004

Filed:

May 31, 2002

Appl. No.:

10/160582

Inventors:

Yong-Jin Wu - Madison CT
Jie Chen - Madison CT
Huan He - Wallingford CT
Alexandre LHeureux - Longueuil, CA
Pierre Dextraze - Laprairie, CA
Jean-Paul Daris - St. Hubert, CA
Gene G. Kinney - Collegeville PA
Steven I. Dworetzky - Middlefield CT
Piyasena Hewawasam - Middletown CT

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07C23720

US Classification:

5142305, 544168, 544146, 544105, 544335, 544336, 544393, 546337, 546175, 546265, 5142378, 5142315, 514357, 514311, 514256, 514332, 5142521, 51425503

Abstract:

There is provided novel cinnamide derivatives of Formula I: wherein R is C alkyl or trifluoromethyl; R is selected from the group consisting of pyridinyl, quinolinyl, thienyl, furanyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, chromanyl, indanyl, biphenylyl, phenyl and substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected-from the group consisting of halogen, C alkyl, C alkoxy, trifluoromethyl, trifluoromethoxy and nitro; R and R are each independently selected from the group consisting of hydrogen, C alkyl, and halogen; R is selected from the group consisting of di(C alkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one or two substituents in which said substituent is independently selected from the group consisting of C alkyl, aminomethyl, hydroxymethyl, chloro or fluoro; R is hydrogen, chloro or fluoro; or R and R taken together are âCH CHâCH CHâ or âX(CH ) Yâ in which X and Y are each independently selected from the group consisting of CH , (CH ) N(R )â and O, wherein m is 1 or 2; n is 0 or 1; and R , R , and R are each independently selected from hydrogen, chloro and fluoro; and R is selected from the group consisting of hydrogen, C alkyl, hydroxyethyl, C alkoxyethyl, cyclopropylmethyl, âCO (C alkyl), and âCH CH NR R in which R and R are each independently hydrogen or C alkyl, which are openers of the KCNQ potassium channels and are useful in the treatment of disorders which are responsive to the opening of the KCNQ potassium channels.

US Patent:

6900210, May 31, 2005

Filed:

Nov 21, 2003

Appl. No.:

10/719538

Inventors:

Yong-Jin Wu - Madison CT, US
Li-Qiang Sun - Glastonbury CT, US
Jie Chen - Madison CT, US
Huan He - Wallingford CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D213/643
C07D239/34
C07D241/18
A61K031/4412
A61K031/513

US Classification:

5142521, 514274, 514314, 514336, 514351, 544316, 544408, 546175, 5462804, 5462814, 5462834, 5462847, 546300

Abstract:

The present invention provides novel heterocyclic amides and related derivatives having the general Formula I wherein R, R, R, R, R, R, A, B and Z are as defined in the specification, or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof which are openers or activators of KCNQ potassium channels. The present invention also provides pharmaceutical compositions comprising said heterocyclic amides and to the method of treatment of disorders sensitive to KCNQ potassium channel opening activity such as migraine or a migraine attack, bipolar disorders, epilepsy, acute and chronic pain and anxiety.

US Patent:

7087609, Aug 8, 2006

Filed:

Nov 21, 2003

Appl. No.:

10/719188

Inventors:

Yong-Jin Wu - Madison CT, US
Li-Qiang Sun - Glastonbury CT, US
Jie Chen - Madison CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/496
C07D 401/04
C07D 401/14
C07D 409/14

US Classification:

51425301, 51425306, 544360, 544363, 544364

Abstract:

The present invention provides piperazinyl phenylethyl amides and related derivatives having the general Formula I.

US Patent:

7592336, Sep 22, 2009

Filed:

May 9, 2006

Appl. No.:

11/430611

Inventors:

Ny Sin - East Hampton CT, US
Paul Michael Scola - Glastonbury CT, US
Nicholas A. Meanwell - East Hampton CT, US
Xiangdong Alan Wang - Guilford CT, US
Li-Qiang Sun - Glastonbury CT, US
Jie Chen - Madison CT, US
Andrew Charles Good - Wallingford CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/5377
A61K 31/454
A61K 31/4025
A61K 31/40
C07D 413/10
C07D 401/10
C07D 207/04

US Classification:

5142355, 514326, 514422, 514423, 544141, 546208, 548518, 548537

Abstract:

Hepatitis C virus inhibitors having the general formula.

US Patent:

8423454, Apr 16, 2013

Filed:

Jan 6, 2012

Appl. No.:

13/344709

Inventors:

Jie Chen - Chappaqua NY, US
Timothy John Breault - Huntersville NC, US
Fernando Cela Diaz - New York NY, US
William Anthony Nobili - Charlotte NC, US
Sandi Setiawan - Charlottle NC, US
Harsh Singhal - Charlotte NC, US
Agus Sudjianto - Charlotte NC, US
Andrea Renee Turner - Rock Hill SC, US
Bradford Timothy Winkelman - Wilmington DE, US

Assignee:

Bank of America Corporation - Charlotte NC

International Classification:

G06Q 40/00

US Classification:

705 38

Abstract:

Embodiments of the present invention relate to methods and apparatuses for determining leading indicators and/or for modeling one or more time series. For example, in some embodiments, a method is provided that includes: (a) receiving first data indicating the value of a total income amount for a plurality of consumers over a period of time; (b) receiving second data indicating the value of a total debt amount for a plurality of consumers over a period of time; (c) selecting a consumer leverage time series that compares the total income amount to the total debt amount over a period of time; (d) modeling the consumer leverage time series based at least partially on the first and second data; (e) determining, using a processor, the value of the cycle component for a particular time; and (f) outputting an indication of the value of the cycle component for the particular time.

US Patent:

20120142653, Jun 7, 2012

Filed:

Jun 2, 2011

Appl. No.:

13/151722

Inventors:

Alicia Regueiro-Ren - Middletown CT, US
Zheng Liu - Beacon Falls CT, US
Jacob Swidorski - Southington CT, US
Nicholas A. Meanwell - East Hampton CT, US
Jie Chen - Madison CT, US
Yan Chen - Guilford CT, US
Ny Sin - East Hampton CT, US

International Classification:

A61K 31/58
A61P 37/00
A61P 31/18
C07J 53/00
A61K 31/56

US Classification:

514176, 540 47, 552514, 514169

Abstract:

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 and C-28 betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.

US Patent:

20120142707, Jun 7, 2012

Filed:

Jun 2, 2011

Appl. No.:

13/151706

Inventors:

Alicia Regueiro-Ren - Middletown CT, US
Jacob Swidorski - Southington CT, US
Zheng Liu - Beacon Falls CT, US
Nicholas A. Meanwell - East Hampton CT, US
Jie Chen - Madison CT, US

International Classification:

A61K 31/235
C07C 63/66
C07D 257/04
C07D 215/50
C07D 333/40
C07D 213/64
C07D 239/28
A61K 31/194
A61K 31/196
A61K 31/41
A61K 31/47
A61K 31/381
A61K 31/4418
A61K 31/505
A61P 31/12
A61P 31/18
A61P 37/02
C07C 309/65
C07C 69/753

US Classification:

514256, 560 6, 562403, 548253, 546170, 549 71, 546285, 544294, 514510, 514569, 514563, 514381, 514311, 514448, 514345, 558 54

Abstract:

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.